Stock Traders Buy Large Volume of X4 Pharmaceuticals Put Options (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of some unusual options trading activity on Monday. Traders acquired 2,515 put options on the stock. This represents an increase of approximately 132% compared to the average daily volume of 1,084 put options.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 52,500 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total value of $46,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Adam S. Mostafa sold 52,500 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total value of $46,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Paula Ragan sold 49,678 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the sale, the chief executive officer now directly owns 765,068 shares of the company’s stock, valued at $673,259.84. The disclosure for this sale can be found here. In the last 90 days, insiders sold 185,708 shares of company stock worth $170,428. 1.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XFOR. SG Americas Securities LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter worth approximately $37,000. Barclays PLC raised its stake in X4 Pharmaceuticals by 334.8% in the third quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after purchasing an additional 294,255 shares in the last quarter. Stonepine Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock worth $5,748,000 after buying an additional 668,422 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in X4 Pharmaceuticals during the third quarter valued at about $678,000. Finally, Bain Capital Life Sciences Investors LLC increased its position in shares of X4 Pharmaceuticals by 6.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after purchasing an additional 955,196 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of X4 Pharmaceuticals in a research report on Friday, March 22nd.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $1.09 on Tuesday. The firm has a market cap of $183.05 million, a PE ratio of -1.82 and a beta of 0.49. X4 Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $2.58. The firm’s fifty day moving average is $1.15 and its 200-day moving average is $0.93. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.34 and a current ratio of 5.34.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05. Sell-side analysts predict that X4 Pharmaceuticals will post -0.47 earnings per share for the current year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.